Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

First UK site uses new fixed Ablatherm-HIFU devices

EDAP TMS : 22 June, 2007  (New Product)
The Capio Springfield Hospital is the first hospital in the UK to use the fixed Ablatherm-HIFU device under EDAP's Revenue-Per-Procedure (RPP) model.
The RPP agreement provides the user with dedicated machine availability at volume preferential terms in return for a guaranteed minimum number of procedures performed.

Capio Springfield joins a growing list of 120 cutting edge centres offering Ablatherm-HIFU across Europe, and more than 150 worldwide.

Mark Perry, business unit sales director for the UK at EDAP said: 'The launch of Ablatherm-HIFU services in the Capio Springfield Hospital continues the European rollout of Ablatherm-HIFU for prostate cancer in major urology centres'.

'Clearly acceptance and use of HIFU is accelerating in Europe where it is being adopted by many of the top urology centres'.

'We are delighted to add another highly regarded centre to our list of clinical and sales champions advancing the cause of Ablatherm-HIFU in Europe'.

Jenny Wright, regional business development manager at the Capio Springfield Hospital added: 'We have already completed 15 successful treatments using a mobile Ablatherm system'.

'This new treatment offers real benefits to an increasing number of our patients, and this is why we have now invested in a fixed machine'.

'Compared to other forms of treatment, Ablatherm has fewer side effects because the accuracy means healthy cells are not destroyed'.

'The treatment has been found to be extremely successful for those patients who are not suitable for surgery or whose cancer has returned after Radiotherapy and has shown very promising long term results'.

'EDAP has spent the last few quarters making substantial investment in the UK to secure broader reimbursement approval and train additional centres,' said Marc Oczachowski, CEO of EDAP.

'We have built a top sales and marketing team with deep expertise of the UK market using internal and external resources'.

'We are confident of our future as the HIFU treatment preferred by the best uro-oncology centres around the globe'.

EDAP is participating in the annual British Association of Urological Surgeons (BAUS) congress held this year in Glasgow, 18 to 21 June 2007.

Stephen Brown, consultant urological surgeon at Stepping Hill Hospital, Stockport, will present quality of life results obtained with Ablatherm-HIFU.
Brown is one of the pioneering users of Ablatherm-HIFU in the UK.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo